Bandaram Pharma Packtech Ltd. Share Price

Bandaram Pharma Packtech has informed that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026, inter alia, to consider and approve 1. Un-audited standalone and consolidated financial results along with Limited Review Report for the quarter ended 30.09.2026. 2. Any other business with the permission of the Chair.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) Cohance Lifesciences has informed that the Company has received an order from the Telangana Pollution Control Board (‘TGPCB’) directing closure of operations at the Company’s manufacturing site at Suryapet, Telangana. The closure order has been issued following an industrial accident that occurred during the manufacturing process, resulting in exposure to one employee on duty at the facility. The employee was immediately provided emergency medical assistance and was subsequently shifted to a specialized hospital in Hyderabad for advanced treatment. Despite receiving the best possible medical care and sustained efforts by the attending medical teams, the employee unfortunately succumbed to his injuries. The Company has immediately initiated appropriate corrective and preventive measures to address the observations stated in the directions issued by TGPCB and expects to promptly submit the requisite representations and compliances to TBPCB, for seeking cancellation of the closure directions at the earliest and allowing the site to resume operations. The Company will keep the Stock Exchanges informed of any material developments in this regard. The details required under Regulation 30 read with Clause 20 of Para A of Part A of Schedule III of the SEBI Listing Regulations and the SEBI Master Circular dated 30 January 2026 are enclosed as Annexure I. The disclosure containing details of the communication received from TGPCB, as required under Regulation 30(13) of the SEBI Listing Regulations read with the Industry Standards prescribed by the Industry Standards Forum (ISF), is enclosed as Annexure II.

Fredun Pharmaceuticals has informed that it enclosed press release titled ‘FREDUN PHARMACEUTICALS ON A GROWTH OVERDRIVE: NET PROFIT SOARS 94%, EBITDA ROCKETS 92% AND REVENUE SURGES 87% IN H1 FY27’. 

The above information is a part of company’s filings submitted to BSE. 

The Revenue for the quarter ended  September 2026 of Rs. 22556.10 millions grew by 16.85 % from Rs. 19303.20 millions.A comparatively good net profit growth of 27.09% to Rs. 3872.90 millions was reported for the quarter ended September 2026 compared to Rs. 3047.40 millions of previous same quarter.Operating Profit saw a handsome growth to 6159.80 millions from 4866.30 millions in the quarter ended September 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	22556.10	19303.20	16.85	43748.50	36772.20	18.97	73367.50	66779.20	9.87
Other Income	189.20	219.20	-13.69	363.40	469.40	-22.58	946.40	712.90	32.75
PBIDT	6159.80	4866.30	26.58	12110.40	9185.70	31.84	18749.30	15963.20	17.45
Interest	46.80	114.60	-59.16	97.20	235.20	-58.67	435.10	630.40	-30.98
PBDT	6113.00	4751.70	28.65	12013.20	8950.50	34.22	18010.00	12517.40	43.88
Depreciation	775.90	668.60	16.05	1522.00	1299.90	17.09	2688.70	2519.70	6.71
PBT	5337.10	4083.10	30.71	10491.20	7650.60	37.13	15321.30	9997.70	53.25
TAX	1464.20	1035.70	41.37	2885.40	1982.80	45.52	3996.10	3490.10	14.50
Deferred Tax	50.00	-9.50	-626.32	170.00	11.00	1445.45	-25.10	81.10	-130.95
PAT	3872.90	3047.40	27.09	7605.80	5667.80	34.19	11325.20	6507.60	74.03
Equity	253.70	253.70	0.00	253.70	253.70	0.00	253.70	253.70	0.00
PBIDTM(%)	27.31	25.21	8.33	27.68	24.98	10.82	25.56	23.90	6.91

The turnover zoomed to Rs. 2061.40 millions, up 52.02% for the September 2026 quarter as against Rs. 1356.00 millions during the year-ago period.Net profit for the quarter ended September 2026 increased significantly by 71.70% to Rs. 501.20 millions from Rs. 291.90 millions.OP of the company witnessed a marginal growth to 835.20 millions from 539.40 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	2061.40	1356.00	52.02	3951.80	2290.60	72.52	5970.30	4774.10	25.06
Other Income	145.70	120.00	21.42	241.30	250.20	-3.56	381.40	696.70	-45.26
PBIDT	835.20	539.40	54.84	1490.90	868.00	71.76	1938.60	2058.00	-5.80
Interest	22.00	24.40	-9.84	47.30	46.70	1.28	100.40	58.70	71.04
PBDT	822.00	499.30	64.63	1487.50	753.80	97.33	2032.40	1541.90	31.81
Depreciation	154.60	136.10	13.59	309.50	266.70	16.05	551.10	488.60	12.79
PBT	667.40	363.20	83.76	1178.00	487.10	141.84	1481.30	1053.30	40.63
TAX	166.20	71.30	133.10	27.60	8.10	240.74	151.60	374.40	-59.51
Deferred Tax	9.50	0.90	955.56	-266.90	45.10	-691.80	76.60	-96.40	-179.46
PAT	501.20	291.90	71.70	1150.40	479.00	140.17	1329.70	678.90	95.86
Equity	195.60	97.80	100.00	195.60	97.80	100.00	195.60	97.80	100.00
PBIDTM(%)	40.52	39.78	1.85	37.73	37.89	-0.44	32.47	43.11	-24.68